2. Academic Validation
  3. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

  • Eur J Med Chem. 2022 Jan 5:227:113906. doi: 10.1016/j.ejmech.2021.113906.
Chao Wang 1,  Yujing Zhang 2,  Jie Wang 3,  Dongming Xing 4
Affiliations

Affiliations

  • 1 The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, 266071, Shandong, China. Electronic address: wangchao20086925@126.com.
  • 2 The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, 266071, Shandong, China; School of Pharmacy, Qingdao University, Qingdao, 266021, Shandong, China. Electronic address: 459233223@qq.com.
  • 3 The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, 266071, Shandong, China. Electronic address: wangj91@qdu.edu.cn.
  • 4 School of Life Sciences, Tsinghua University, Beijing, 100084, China. Electronic address: xdm_tsinghua@163.com.
PMID: 34656901 DOI: 10.1016/j.ejmech.2021.113906
Abstract

Proteolysis targeting chimeras (PROTACs), which hijack proteins of interest (POIs) and recruit E3 Ligases for target degradation via the ubiquitin-proteasome pathway, are a novel drug discovery paradigm that has been widely used as biological tools and medicinal molecules with the potential of clinical application value. To date, a wide variety of small molecule PROTACs have been developed. Importantly, VHL-based PROTACs have emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins. VHL-based PRTOACs have been developed for the treatment of diseases that are difficult to be dealt with by conventional methods, such as radiotherapy, chemotherapy, and small molecule inhibitors. In this review, the recent advances of VHL-based PRTOACs were summarized, and the chances and challenges associated with this area were also highlighted.

Keywords

Degradation; PROTACs; Promising treatment; Ubiquitination; VHL.

Figures
Products